Epidolex

GW Pharmaceuticals plc (NASDAQ: GWPH) released Monday preliminary unaudited financial results. Net sales for the company's fourth-quarter are expected to be around $148 million. For the full year, GW anticipates net sales of $526 million while its total Epidolex...

By: William Sumner Have you ever experienced sticker shock? If you're like some of the people following the development of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CBD-based drug, Epidiolex, then odds are you probably have. After gaining approval from the FDA, GW released the estimated price...

Elemer Piros of Cantor Fitzgerald maintains an Overweight rating on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) with a $208 price target following the company's "encouraging" Phase 2 glioama data report. Success In GBM As part of the Phase 2 study, 21 patients who were treated with GW's mixed THC:CD...

Shares of GW Pharmaceuticals PLC - ADR (NASDAQ: GWPH) soared Wednesday from around $83 per share to close at $104.03 after Reuters reported the company is in talks with an investment banks to consider strategic alternatives. GW Pharmaceuticals is a developer of marijuana-based epilepsy...

Shares of GW Pharmaceuticals PLC - ADR (NASDAQ: GWPH) spiked higher by more than 5 percent early Thursday morning after the company reported that data from a physician-led study into Epidiolex "reduced seizure frequency" across multiple drug-resistant epilepsy syndromes and seizure types and was "...